U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.» Read More
Options move on pharmaceutical speculation and oil price drops.
Sometimes a stock is hot and other time it just burns. Following are the Fast Money misfires.
The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"
Following are the day’s biggest winners and losers. Find out why shares of General Motors and Dryships popped while Teva and RBS dropped.
After hours Morgan Stanley recommended investors buy Lehman Brothers stock and set a price target of $31. What's the "Word on the Street?"
It was an ugly first half for the stock market and now that the goal posts have been moved for the economic recovery, expect a rough game in the second half.
The Dow closed sharply lower Friday, registering its third triple-digit loss in four sessions. What's the "Word on the Street?"
The Lightning Round is extended in this CNBC.com exclusive feature.
On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.
Following are the day’s biggest winners and losers. Find out why shares of Marvel and Disney popped while Garmin and BHP Billiton dropped.
This geothermal energy play has plenty of room to grow.
As the Dow, Nasdaq and S&P slide into negative territory, CNBC asked the experts how to bolster your investments.
Haim Israel of Merrill Lynch in Jerusalem has some ideas about smaller Israeli companies that might have escaped the attention of U.S. investors.
When Apple's Steve Job's picked Israeli Yael Naim's "New Soul" for the Mac Air commercial, it wasn't the first time Silicon Valley connected with Israel. In fact, Israel has more companies traded on the tech heavy Nasdaq than any other country outside the United States. As Israel celebrates its 60th anniversary of statehood, here are some more facts and figures on the Israeli economy and markets...
AstraZeneca has settled U.S. patent litigation against India's Ranbaxy Laboratories over its top-selling drug, ulcer pill Nexium, securing future sales and sending its shares soaring.
All the excitement in the United States this week may have distracted investors from the global investment scene. Five-star fund co-manager Wendy Trevisani suggests that would be a mistake, and she has some prominent international names to prove it.
This could be the sector to own by next fall's presidential election.
When the economy rebounds, where's your portfolio going to be? UBS says that's a question to answer right now. The bank released what it calls its "'New' Nifty Fifty," a list of 50 companies from around the world that can use today's troubling market conditions to position themselves to thrive when the economy rebounds. (PART 3)
It's a booyah-free zone. There goes Swifty!Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.